



1



2



Case Study: Biopharma Company A

- Global R&D network
- Numerous lines of fundamental research (published or intended to be published)
- Academic, government, and private collaborations
- Development facilities conducting proprietary research
- Production facilities manufacturing API and finished drugs

3

3



Fundamental Research and Publication

Publicly available technologies
(Not Subject to the EAR)

INPUT

Preexisting Export
Controlled Technologies
(Subject to the EAR)



Results of research published:
(Fundamental Research)
(Not Subject to the EAR)

OUTPUT

Results of research withheld from
publication or specific publication
restrictions
(Subject to the EAR)

4

4



Chimeric Viruses



Ebolavirus (1C351)




Genetically modified Vesicular Stomatitis Virus
(1C353 until formulated as deliverable vaccine, then 1C991)

5

5



SARS-CoV-2




6

6




Chimeric Viruses



7



Fundamental Research and Publication



8



Export Licenses

Materials

- SARS-CoV-2 (EAR99)
- SARS-CoV (1C351.a.47)
- Vesicular stomatitis virus (1C351.a.56)
- Plasmids with VSV elements (1C353.a.1)
- Plasmids with SARS-CoV-2 elements (EAR99)
- Chimeric VSV/SARS-CoV-2 virus (1C353.a.1)
- Finished vaccine (1C991.a)

Technologies (production)

- Genetically engineering chimeras (NSEAR)
- Plasmids with VSV elements (1E001)
- Plasmids with SARS-CoV-2 elements (EAR99)
- Chimeric VSV/SARS-CoV-2 virus (1E001)
- Finished vaccine (EAR99)

9

9



Export Licenses



Research Labs



Production facilities



Public health authorities



Consulting and translation firms

10

10

Bureau of Industry and Security
BIS 2022 UPDATE CONFERENCE ON
EXPORT CONTROLS & POLICY





Export Licenses - Summary

- Over 400 parties
- 75 countries
- Authorized technology exchanges among and between all parties
- Authorized material transfers among and between all the Company A subsidiaries and facilities
- Applied early in the process
- Considered diverse possibilities
- Communicated frequently with BIS

11

11

Bureau of Industry and Security
BIS 2022 UPDATE CONFERENCE ON
EXPORT CONTROLS & POLICY



Questions?

12